Roivant Sciences (ROIV) Stock Price
Roivant Sciences Price
Revenue has compounded at 19.9% per year over the past 7 years to 8.26 M USD. Roivant Sciences's net margin stands at -3,629.2%, down from -1,528.9% several years earlier. Analysts set a median price target of 41.00 USD, implying 22.5% above the current price. Of 19 analysts, 17 rate the stock a buy — an overall Buy consensus.
Roivant Sciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Roivant Sciences business model & stock analysis
Frequently asked questions about Roivant Sciences
Roivant Sciences Ltd has a unique business model focused on creating and developing innovative biopharmaceutical companies. They identify and acquire promising drug candidates from research organizations and pharmaceutical companies, and then allocate resources to further develop and commercialize these potential therapies. By operating a centralized infrastructure, Roivant provides expertise in areas such as clinical development, regulatory affairs, and commercialization, enabling their subsidiary companies to focus on scientific advancements. Their mission is to transform the traditional drug development process and bring important therapies to patients in need. Roivant Sciences Ltd is driven by a commitment to improve healthcare options and deliver value to their stakeholders.
Roivant Sciences Ltd is primarily active in the pharmaceutical and healthcare industries. With a focus on developing and commercializing innovative therapies, Roivant Sciences Ltd aims to improve patient care and address unmet medical needs. By leveraging their unique approach to drug discovery and development, the company strives to make a significant impact in various therapeutic areas. Through strategic partnerships and a robust pipeline of investigational drug candidates, Roivant Sciences Ltd continues to drive advancements in healthcare with its commitment to innovation and improving patient outcomes.
The main competitors of Roivant Sciences Ltd in the market are Actinium Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., Akorn, Inc., and Alkermes plc.
Roivant Sciences Ltd is a well-established pharmaceutical company with a rich history and background. Founded in 2014, Roivant Sciences has quickly gained recognition for its innovative approach to developing and commercializing transformative drugs. Headquartered in Basel, Switzerland, the company focuses on harnessing advanced technologies and data-driven solutions to tackle unmet medical needs. With a strong emphasis on strategic partnerships and collaborations, Roivant Sciences has attracted global attention for its success in bringing novel therapies to market. As a leading player in the healthcare industry, Roivant Sciences continues to revolutionize the treatment landscape, earning a reputation for its commitment to improving patients' lives and addressing critical healthcare challenges.
Roivant Sciences Ltd has achieved significant milestones in its journey. With a focus on innovative healthcare solutions, the company has made noteworthy achievements. One of the notable milestones is the successful approval of its flagship product, [Company Name], by regulatory authorities. Additionally, Roivant Sciences Ltd has established key strategic partnerships with leading pharmaceutical companies, further enhancing its global presence and research capabilities. The company's commitment to advancing medical research and development is exemplified by its continuous efforts in pioneering groundbreaking therapies and treatments. As a result, Roivant Sciences Ltd has positioned itself as a trusted and trailblazing player in the healthcare industry.
Roivant Sciences Ltd primarily operates in various countries and regions globally. As a biopharmaceutical company, Roivant Sciences Ltd has a significant presence in the United States, where its headquarters are located. The company has also expanded its operations to other regions, including Europe, Asia, and Latin America. With a focus on developing and commercializing innovative therapies, Roivant Sciences Ltd continues to establish a strong international footprint, leveraging its expertise to address patients' unmet needs in different markets worldwide.
Roivant Sciences Ltd represents a commitment to innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on transforming the biopharmaceutical industry, Roivant Sciences aims to address unmet medical needs by developing and commercializing novel therapies. The company values scientific excellence and prioritizes the advancement of groundbreaking technologies and therapeutics. Roivant Sciences also strives for transparency, integrity, and respect in all its interactions, forming strategic partnerships with leading healthcare organizations and experts worldwide. Through its core values and corporate philosophy, Roivant Sciences is dedicated to improving healthcare outcomes and enhancing the overall well-being of patients.
Analysts currently set an average price target of 40.00 USD for the Roivant Sciences stock (median: 41.00 USD), implying +19.5 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Roivant Sciences stock: 17 recommend buying, 2 holding and 0 selling.
Converted at the current exchange rate, the Roivant Sciences share trades at 29.78 EUR (33.47 USD).
The Roivant Sciences share (ROIV) is listed on 4 stock exchanges, including: NASDAQ (ROIV), Frankfurt (87S.F), München (87S.MU), Düsseldorf (87S.DU).
Roivant Sciences Ltd is a global biotech company headquartered in Basel, Switzerland. They focus on developing innovative therapies to address unmet medical needs of people worldwide. Roivant Sciences specializes in creating "Vants," separate operating subsidiaries that specialize in specific therapy areas. They identify specific clinical needs where there is no suitable therapy available and then establish a specific Vant dedicated to the development of therapies in that area. Some of Roivant Sciences' Vants include Axovant, which focuses on developing therapies for neurological diseases such as Alzheimer's and dementia. Enzyvant is dedicated to developing new treatments for rare, severe diseases, particularly for patients where treatment is no longer possible due to the absence of existing therapies. Myovant, another Vant of Roivant Sciences, focuses on developing therapies for women's health conditions such as endometriosis and infertility. Roivant Sciences drives the development of innovative therapies through partnerships and spin-offs of existing companies, and expands its therapeutic focus through strategic acquisitions. For example, in 2019, Roivant acquired Silicon Therapeutics, specializing in computer-assisted drug modeling. In addition to its Vants, Roivant Sciences also operates data prediction models through its Roivant Digital division and utilizes artificial intelligence and machine learning to discover new molecules and therapeutic approaches. These technologies complement the work of the company's Vants and enable faster and more efficient therapy development. Overall, Roivant Sciences has focused on developing therapies for diseases with high medical necessity. At the same time, the company strives to accelerate the development of new therapies by promoting collaboration between different disciplines such as biotechnology, software development, and data analysis. As the demand for novel therapeutic options remains high, Roivant Sciences is well positioned to achieve further groundbreaking developments in the industry in the coming years.
The revenue of Roivant Sciences is 8.26 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Roivant Sciences is -299.77 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Roivant Sciences is currently -80.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Roivant Sciences stock.
The price-to-sales ratio (P/S) of Roivant Sciences is currently 2,920.63. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Roivant Sciences stock.
The Eulerpool Quality Score for Roivant Sciences is 2/10.
The ISIN of Roivant Sciences is BMG762791017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Roivant Sciences is A3C4MS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Roivant Sciences is ROIV. The ticker symbol is used to trade Roivant Sciences shares on the stock exchange.
Roivant Sciences stock
Roivant Sciences Peer Group
Roivant Sciences Ticker
Roivant Sciences FIGI
All fundamentals and in-depth analysis of Roivant Sciences
Our stock analysis for Roivant Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roivant Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.